DERMATA THERAPEUTICS INC (DRMA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.21-1.63%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · DRMA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Execute the commercial launch of the first direct-to-consumer skincare product, Tome Foundational Treatment, expected August 25, 2026.
Stated as a priority in 3 of last 3 quarters. Management consistently targeted a mid-2026 launch, culminating in the August 25, 2026 launch date announced in 2026-Q2. This launch marks the company’s transition to commercial revenue generation, matching management’s stated timeline and delivering on the strategic pivot.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Dermata expects to launch its first product on August 25, 2026.”
“We anticipate being ready to launch the Foundational Treatment in the middle of 2026.”
“Planned mid-2026 launch of our once-weekly Foundational Treatment for skin renewal.”
Control operating expenses and cash burn to sustain operations into late 2026 and beyond.
Stated as a priority in 3 of last 3 quarters. Cash decreased from $7.5M at 2025-Q4 to $4.4M at 2026-Q2, with operating losses increasing from -$1.9M in 2026-Q1 to -$3.0M in 2026-Q2. Management’s focus on managing cash burn and reallocating resources toward commercialization shows limited progress given the cash decline and rising losses.
“Cash resources sufficient to fund operations into the fourth quarter of 2026.”
“Cash resources sufficient to fund operations into the first quarter of 2027.”
“Focus on reallocating resources toward pre-commercial launch and reducing R&D expenses.”
Develop and commercialize additional DTC skincare products following the Foundational Treatment launch.
Stated as a priority in 3 of last 3 quarters. Management consistently communicated plans to develop and launch a second DTC skincare product following the Foundational Treatment. No revenue or launch milestones for the second product are yet reported, indicating ongoing development with limited substantive delivery so far.
“Continue development of a second DTC product, expected to launch after Foundational Treatment.”
“Working on its second skincare product expected to launch after Foundational Treatment.”
“Plans for additional innovations planned to follow initial product launch.”
Raise capital via private placements and At The Market (ATM) offerings to fund operations and development programs.
Over the trailing year it converted 0.88x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
25 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.